高级检索
当前位置: 首页 > 详情页

A Review of MicroRNA in Uveal Melanoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Ophthalmology,Beijing Tongren Eye Center,Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment,Beijing Ophthalmology & Visual Sciences Key Lab,Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology,Beijing Tongren Hospital,Capital Medical University,Beijing,People’s Republic of China
出处:
ISSN:

关键词: uveal melanoma microRNA biomarker immune response review

摘要:
Uveal melanoma (UM) is the most common and aggressive primary intraocular tumor in adults. UM is classified as a malignant tumor with a strong tendency of metastasis, which always leads to poor outcomes. At present, the pathogenesis of UM remains unclear and lacks effective therapies. Recent studies have shown that microRNAs (miRNAs), defined as a group of 21-23 nucleotides single-stranded noncoding RNAs, play a significant role in UM. By binding to the complementary sites within the 3' untranslated region (3'UTR) of message RNAs (mRNAs), miRNAs regulate genes by decaying mRNAs or inhibiting their translation. Thus, miRNAs can modulate various biological behaviors of tumors, including cell proliferation, invasion and metastasis. Furthermore, miRNAs have shown clinical applications by serving as biomarkers for diagnosis and prognosis, regulating immune response, and functioning as epigenetic regulators. It is reasonable to believe that miRNAs have wide application prospects in the early diagnosis and therapy of UM.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 生物工程与应用微生物 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 3 区 生物工程与应用微生物 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q2 ONCOLOGY
最新[2023]版:
Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Ophthalmology,Beijing Tongren Eye Center,Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment,Beijing Ophthalmology & Visual Sciences Key Lab,Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology,Beijing Tongren Hospital,Capital Medical University,Beijing,People’s Republic of China
通讯作者:
通讯机构: [1]Department of Ophthalmology,Beijing Tongren Eye Center,Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment,Beijing Ophthalmology & Visual Sciences Key Lab,Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology,Beijing Tongren Hospital,Capital Medical University,Beijing,People’s Republic of China [*1]Department of Ophthalmology,Beijing Tongren Eye Center,Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment,Beijing Ophthalmology & Visual Sciences Key Lab,Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology,Beijing Tongren Hospital,Capital Medical University,1 Dong Jiao Min Lane,Beijing 100730,People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21166 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)